Physician profile
Henry A Doenlen
NPI 1801831458
$1,993.17
in general payments reported to CMS, 2019-2025
19 companies · $940 in 2025
The $940 reported for 2025 was more than what 85% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.71 · 2022: $24.29 · 2023: $301 · 2024: $644 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $188.95 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.43 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $173.08 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $161.40 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $158.71 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $153.21 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $149.56 | 2022-2025 | Azstarys |
| Alkermes, INC. | $138.24 | 2023-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $134.41 | 2024-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $115.95 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $94.29 | 2024-2025 | Fanapt |
| Lundbeck LLC | $83.94 | 2024-2025 | Rexulti |
| Neos Therapeutics, LP | $73.76 | 2019-2023 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $62.50 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $39.93 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $21.37 | 2025 | Wellbutrin, Aplenzin |
| Jazz Pharmaceuticals INC. | $19.28 | 2025 | |
| Neuronetics, INC. | $18.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.62 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Doenlen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.